FierceBiotechFierceBioResearcherFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

Acclaimed scientist preps first skin cancer vax trial

Tools
  • Email
  • Print
  • Comment
  • Contact Author
  • Reprint

Australia's Ian Frazer has been using his knowledge of human papilloma virus to create an experimental jab to prevent skin cancer. And now he says he's ready to launch the first human trial of a new vaccine that has already proven effective in preventing skin cancer in animals.

In the study, researchers will vaccinate girls aged 10 to 12 and track its effectiveness in preventing skin cancer as they age. Sunny Australia has the highest rate of skin cancer in the world, with 1,600 people dying from the cancer each year. As with the HOV vaccine Gardasil, the vaccine targets the papilloma virus, which spurs abnormal cells to turn cancerous.

"My entire career has been focused on understanding the interaction between papillomavirus and the cancers they affect,'' Prof Frazer told the Daily Telegraph. "We know it causes at least five per cent of all cancers globally so one in 20 of the cancers that people get is caused by papilloma virus. It's a huge issue.''

- read the report from the Daily Telegraph

Related Articles:
Therapy credited in skin cancer cure
Synta therapy slows spread of melanoma (Sept 2007)
In Phase III, Gardasil prevents HPV in men
FDA grants Gardasil two new indications

More stories about Ian Frazier   HPV   Clinical trial   cancer vaccine   Vaccine  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.